Physician profile
Steven Schaeffer
NPI 1477817336
$1,416.16
in general payments reported to CMS, 2019-2025
15 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2021: $13.44 · 2022: $38.81 · 2023: $278 · 2024: $711 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $623 · Travel and Lodging: $508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $623.40 |
| Travel and Lodging | $507.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fortis Surgical, LLC | $356.01 | 2024 | |
| Linvatec Corporation | $249.97 | 2024-2025 | Biobrace 23mm, Colink Vallux, Ibs |
| Arthrex, INC. | $204.95 | 2024 | |
| Stryker Corporation | $144.28 | 2023 | Ortholoc 3di Crosscheck |
| Abbott Laboratories | $126.96 | 2019 | |
| Horizon Therapeutics Plc | $113.62 | 2023 | Krystexxa |
| Bioventus LLC | $48.14 | 2023-2025 | Exogen Ultrasound Bone Healing System, Exogen Ultrasound Bone Healing System |
| Smith+Nephew, INC. | $29.09 | 2019 | |
| Nevro Corp. | $26.35 | 2022 | |
| Nabriva Therapeutics, Plc | $25.90 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $24.51 | 2019 | |
| Zimmer Biomet Holdings, INC. | $21.51 | 2019 | |
| Melinta Therapeutics, LLC | $18.07 | 2019 | |
| Organogenesis INC. | $14.34 | 2024 | |
| Depuy Synthes Sales INC. | $12.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Schaeffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.